MX2019009106A - Anticuerpos procoagulantes. - Google Patents

Anticuerpos procoagulantes.

Info

Publication number
MX2019009106A
MX2019009106A MX2019009106A MX2019009106A MX2019009106A MX 2019009106 A MX2019009106 A MX 2019009106A MX 2019009106 A MX2019009106 A MX 2019009106A MX 2019009106 A MX2019009106 A MX 2019009106A MX 2019009106 A MX2019009106 A MX 2019009106A
Authority
MX
Mexico
Prior art keywords
factor
antibodies
fixa
binding
activated form
Prior art date
Application number
MX2019009106A
Other languages
English (en)
Inventor
Østergaard Henrik
Chen Jianhe
Thorn Karina
Gram Hansen Bjarne
Nors HARNDAHL Mikkel
Yang Zhiru
J Greisen Per
Johansson Eva
Svensson Anders
ZHU Haisun
Zhou Rong
Bruun Johnsen Laust
Grønbech Rasch Morten
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2019009106A publication Critical patent/MX2019009106A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a anticuerpos procoagulantes mejorados que incluyen anticuerpos biespecíficos capaces de unirse al factor de coagulación IX (FIX) o su forma activada IXa (FIXa) y opcionalmente al factor X (FX) y su forma activada Xa (FXa) y que promueven la activación de FX por FIXa, anticuerpos que unen sus epítopos y métodos y composición para tratar sujetos que padecen de una coagulopatía tal como hemofilia A.
MX2019009106A 2017-02-01 2018-02-01 Anticuerpos procoagulantes. MX2019009106A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2017072796 2017-02-01
CN2017105556 2017-10-10
CN2017115210 2017-12-08
EP18154489 2018-01-31
PCT/EP2018/052550 WO2018141863A1 (en) 2017-02-01 2018-02-01 Procoagulant antibodies

Publications (1)

Publication Number Publication Date
MX2019009106A true MX2019009106A (es) 2019-09-10

Family

ID=61521468

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009106A MX2019009106A (es) 2017-02-01 2018-02-01 Anticuerpos procoagulantes.

Country Status (16)

Country Link
US (1) US12084512B2 (es)
EP (2) EP3848396A1 (es)
JP (3) JP7366747B2 (es)
KR (1) KR20190112747A (es)
CN (1) CN110248964B (es)
AU (1) AU2018216008A1 (es)
BR (1) BR112019015611A2 (es)
CA (1) CA3051639A1 (es)
CL (1) CL2019002136A1 (es)
CO (1) CO2019008461A2 (es)
IL (1) IL268140B2 (es)
MX (1) MX2019009106A (es)
PE (1) PE20191347A1 (es)
PH (1) PH12019501708A1 (es)
TW (1) TWI837084B (es)
WO (1) WO2018141863A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI837084B (zh) 2017-02-01 2024-04-01 丹麥商諾佛 儂迪克股份有限公司 促凝血抗體
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
US11193588B2 (en) 2017-08-09 2021-12-07 Mainspring Energy, Inc. Reinforced sealing rings
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
EP3830135A1 (en) 2018-08-01 2021-06-09 Novo Nordisk A/S Improved procoagulant antibodies
WO2020115281A1 (en) * 2018-12-07 2020-06-11 Baxalta GmbH Proteinaceous molecules binding factor ixa and factor x
WO2020114615A1 (en) * 2018-12-07 2020-06-11 Baxalta GmbH Bispecific antibodies binding factor ixa and factor x
WO2020114614A1 (en) * 2018-12-07 2020-06-11 Baxalta GmbH Proteinaceous molecules binding factor ixa and factor x
WO2020115283A1 (en) * 2018-12-07 2020-06-11 Baxalta GmbH Bispecific antibodies binding factor ixa and factor x
US20220064327A1 (en) 2018-12-21 2022-03-03 Kymab Limited Fixaxfx bispecific antibody with common light chain
EP3956359A1 (en) * 2019-04-17 2022-02-23 Novo Nordisk A/S Bispecific antibodies
KR20220044946A (ko) * 2019-07-03 2022-04-12 크리스탈 바이오사이언스 주식회사 항-b7-h3 항체 및 이의 사용 방법
EP4097141A1 (en) 2020-01-30 2022-12-07 Novo Nordisk A/S Bispecific factor viii mimetic antibodies
US20230287142A1 (en) * 2020-07-06 2023-09-14 President And Fellows Of Harvard College Histamine binding polypeptides and uses thereof
WO2023111018A1 (en) * 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag Antibodies against coagulation factor x and uses thereof
KR20240007881A (ko) 2022-07-08 2024-01-17 노보 노르디스크 에이/에스 FVIII(a)를 치환할 수 있는 매우 강력한 ISVD 화합물
WO2024008904A2 (en) 2022-07-08 2024-01-11 Novo Nordisk A/S Highly potent isvd compounds capable of substituting for fviii(a)

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0658168T3 (da) 1992-08-27 2001-01-22 Sanquin Bloedvoorziening Antistoffer, som er specifikke for et hæmostatisk protein, anvendelse heraf til isolering af intakt protein, hæmostatiske p
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
JP2002510321A (ja) 1997-07-03 2002-04-02 スミスクライン・ビーチャム・コーポレイション 抗−第ＩＸ因子 Ｆａｂフラグメントの結晶構造およびペプチド模倣物デザインのための使用方法
WO2000007626A1 (en) 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
DE69901569T2 (de) 1998-08-28 2002-12-19 Genentech, Inc. Humane antikörper gegen faktor ix/ixa
US7109170B2 (en) 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US20020098188A1 (en) 2000-05-24 2002-07-25 Riken Blood coagulation factor-activating protein and antibody thereto
ES2333598T5 (es) 2003-05-06 2013-09-04 Biogen Idec Hemophilia Inc Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
ES2494921T3 (es) 2005-04-08 2014-09-16 Chugai Seiyaku Kabushiki Kaisha Anticuerpo que sustituye la función del factor VIII de coagulación sanguínea
JP5997443B2 (ja) 2008-05-16 2016-09-28 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 標的化凝固因子およびそれを使用する方法
AU2009284393B2 (en) 2008-08-22 2014-09-25 Takeda Pharmaceutical Company Limited Methods for treating bleeding disorders
EP2349341B1 (en) 2008-10-15 2013-10-09 Baxter Healthcare SA Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
ES2607935T3 (es) 2009-03-30 2017-04-04 Portola Pharmaceuticals, Inc. Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos
EP2470559B1 (en) 2009-08-24 2017-03-22 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
WO2011080322A1 (en) 2009-12-30 2011-07-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of prognosing the outcome of acquired hemophilia and of treatment of hemophilia
CA2786758A1 (en) 2010-01-14 2011-07-21 Baxter International Inc. Methods and compositions for treating bleeding disorders
CN103221429A (zh) 2010-09-22 2013-07-24 诺沃—诺迪斯克有限公司 治疗因子viii抗体
KR101398363B1 (ko) 2010-11-17 2014-05-22 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
WO2012098089A1 (en) 2011-01-19 2012-07-26 Bayer Pharma Aktiengesellschaft Binding proteins to inhibitors of coagulation factors
WO2013078089A1 (en) 2011-11-22 2013-05-30 Biogen Idec Ma Inc. Anti-tim-1 antibodies and uses thereof
US20160296602A1 (en) 2013-03-20 2016-10-13 Novo Nordisk A/S Dosing Regimen
CN103396494B (zh) 2013-04-27 2015-04-01 江苏省疾病预防控制中心 一种凝血因子ix的单克隆抗体
TW201605904A (zh) 2013-11-07 2016-02-16 諾佛 儂迪克股份有限公司 治療凝血病變之新穎方法及抗體
MX2017010734A (es) * 2015-04-17 2017-12-04 Hoffmann La Roche Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos.
CN117986372A (zh) 2016-07-29 2024-05-07 中外制药株式会社 显示增加的备选fviii辅因子功能活性的双特异性抗体
BR112019010349A2 (pt) 2016-11-23 2019-10-08 Bioverativ Therapeutics Inc Anticorpos anti-fixa, anti-fxz e antifxa, molécula biespecífica, ácido nulceico, composiçãofarmacêutica e uso dos anteriores
TWI837084B (zh) 2017-02-01 2024-04-01 丹麥商諾佛 儂迪克股份有限公司 促凝血抗體
JP7209298B2 (ja) 2017-03-31 2023-01-20 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｉｘ因子異常症の予防および／または治療に用いられる医薬組成物
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
JP6496095B1 (ja) 2017-09-29 2019-04-03 中外製薬株式会社 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）補因子機能代替活性を有する多重特異性抗原結合分子および当該分子を有効成分として含有する薬学的製剤
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies

Also Published As

Publication number Publication date
EP3577140A1 (en) 2019-12-11
IL268140B2 (en) 2024-04-01
WO2018141863A9 (en) 2018-11-22
PE20191347A1 (es) 2019-09-30
WO2018141863A1 (en) 2018-08-09
US12084512B2 (en) 2024-09-10
RU2019125970A (ru) 2021-03-02
IL268140A (en) 2019-09-26
AU2018216008A1 (en) 2019-08-01
KR20190112747A (ko) 2019-10-07
PH12019501708A1 (en) 2020-06-01
JP2023179628A (ja) 2023-12-19
TW201835107A (zh) 2018-10-01
JP2020506927A (ja) 2020-03-05
US20210388114A1 (en) 2021-12-16
JP7366747B2 (ja) 2023-10-23
CL2019002136A1 (es) 2019-10-18
RU2019125970A3 (es) 2021-06-18
JP2021176898A (ja) 2021-11-11
TWI837084B (zh) 2024-04-01
CN110248964B (zh) 2024-08-27
BR112019015611A2 (pt) 2020-03-17
EP3848396A1 (en) 2021-07-14
CA3051639A1 (en) 2018-08-09
CN110248964A (zh) 2019-09-17
CO2019008461A2 (es) 2020-01-17
IL268140B1 (en) 2023-12-01

Similar Documents

Publication Publication Date Title
PH12019501708A1 (en) Procoagulant antibodies
PH12021550117A1 (en) Improved procoagulant antibodies
PH12019501126A1 (en) Bispecific antibodies binding to coagulation factor ix and ciagulation factor x
CY1124118T1 (el) Αντισωματα προσδεσης θυμικης στρωματικης λεμφοποιητινης (tslp) και μεθοδοι χρησης των αντισωματων
EA201691470A1 (ru) Белки, связывающие калликреин плазмы, и их применение для лечения наследственного ангионевротического отека
SA518390944B1 (ar) أجسام مضادة لمثبط مسار عامل نسيج واستخداماتها
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
MX2014015830A (es) Anticuerpos lsr y usos de los mismos para el tratamiento de cancer.
MX2021002690A (es) Anticuerpos anti-avb8 y composiciones y usos de los mismos.
TW200730624A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
TW200745162A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
MD3463435T2 (ro) Anticorpi impotriva alfa sinucleinei și utilizări ale acestora
EA201490850A1 (ru) Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
EA201690064A1 (ru) Антитела к лектин-подобному рецептору 1 окисленных ldl и способы применения
PH12015502829A1 (en) Lectin-like oxidized ldl receptor1 antibodies and methods of use
MY184189A (en) Methods of treating nail and scalp psoriasis
EA201590918A1 (ru) Антитела к bmp-6
MX2019013700A (es) Composiciones y metodos para el tratamiento de complicaciones y trastornos que se relacionan con el factor de von willebrand.
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
NZ629700A (en) Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
AR114539A1 (es) Anticuerpos procoagulantes mejorados
SG10201807066UA (en) Peptides and methods of use
MX2022005718A (es) Anticuerpos tmem219 y usos terapeuticos de los mismos.
EA202092640A1 (ru) Способы и композиции для лечения хронической крапивницы